A Study to Evaluate the Efficacy of Androxal in Improving Glycemic Control in Men With Secondary Hypogonadism or Adult-onset Idiopathic Hypogonadotropic Hypogonadism (AIHH) and Type 2 Diabetes Mellitus With Sub-Optimum Treatment

Trial Profile

A Study to Evaluate the Efficacy of Androxal in Improving Glycemic Control in Men With Secondary Hypogonadism or Adult-onset Idiopathic Hypogonadotropic Hypogonadism (AIHH) and Type 2 Diabetes Mellitus With Sub-Optimum Treatment

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2014

At a glance

  • Drugs Enclomifene (Primary)
  • Indications Hypogonadism; Type 2 diabetes mellitus
  • Focus Pharmacodynamics; Therapeutic Use
  • Sponsors Repros Therapeutics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 Apr 2013 Results reporting changes in hormone levels, including changes in insulin-like growth factor-1 levels, presented at the 104th Annual Meeting of the American Association for Cancer Research.
    • 10 Apr 2013 Repros Therapeutics was issued a patent for Androxal for the treatment of type 2 diabetes mellitus based on findings from this trial, according to a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top